Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Head & Neck 1Gastrointestinal 1

Conditions

Colorectal Neoplasms 16Rectal Neoplasms 4Colonic Neoplasms 4Stomach Neoplasms 3Neoplasm Metastasis 3Neoplasms 2Biliary Tract Neoplasms 2Sarcoma, Ewing 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Recurrence 1Prostatic Neoplasms 1Metastatic Gastric Adenocarcinoma 1Lung Neoplasms 1Head and Neck Neoplasms 1Gastric Cancer Adenocarcinoma Metastatic 1Gallbladder Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Dihydropyrimidine Dehydrogenase Deficiency 1Desmoid Tumors 1Craniopharyngioma 1Colorectal Cancer Metastatic 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Advanced/Metastatic Solid Tumors 1Advanced Solid Tumors 1Adenomatous Polyposis Coli 1Adenocarcinoma Of Esophagus 1

Interventions

pembrolizumab 25Cisplatin 17Carboplatin 13Radiotherapy 12Cetuximab 9Blood Specimen Collection 9Docetaxel 8Paclitaxel 7Fluorouracil 7Drug Therapy 7toripalimab 6tislelizumab 4nimotuzumab 4atezolizumab 4Radiation 4Chemoradiotherapy 4fludarabine 3Surveys and Questionnaires 3Surgical Procedures, Operative 3Standard of Care 3Radiotherapy, Intensity-Modulated 3Cyclophosphamide 3Biopsy 3130-nm albumin-bound paclitaxel 3cemiplimab 2avelumab 2X-Rays 2Tocopherols 2Tiragolumab 2Therapeutics 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Head and Neck Neoplasms × trifluridine tipiracil drug combination × Clear all
NCT04999761 2024-09-25

AB122 Platform Study

Taiho Pharmaceutical Co., Ltd.

Phase 1 Recruiting
917 enrolled
GastrointestinalHead & NeckSarcomaThoracic

Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms, Sarcoma, Alveolar Soft Part

Data powered by HemOnc (CC BY 4.0) Colophon âš¡